Cervilenz Inc. receives CE Mark and Additional International Patents for its Signature CerviLenz® Device

CLEVELAND, OH – November 17, 2011
Cervilenz Inc. recently received its CE Mark and ISO 13485 Certification for the CerviLenz® device. This innovative medical device is used to measure vaginal cervical length to help obstetricians identify and manage pregnant women at high risk for premature birth.

Cervilenz Inc. also added to its already robust patent portfolio for the device. The company now holds 12 issued patents, including 5 in the United States, 5 in Europe (France, Germany, Italy, UK, and Spain), 1 in Japan, and 1 in Turkey. Ten additional patent applications are pending.

The CerviLenz device gives health care providers a reliable cervical length measurement during any prenatal visit. Cervical length measurements are important because if a pregnant woman’s cervix shortens too soon, she is at high risk for a premature birth and needs specialized care. Research has shown that vaginal progesterone treatment can prevent early deliver in women with a prematurely short cervix.

“This is an exciting time for us,” said Dean Koch, President and CEO of Cervilenz Inc. “The need for cervical length measurements is growing rapidly with advances in progesterone therapy. Current technology alone will not be able to meet that need, and our new device is the perfect solution. We are confident that CerviLenz will play a vital role in reducing the rate of prematurity worldwide.”

Today is World Prematurity Day. There are nearly 13 million premature births worldwide every year, and over 1 million of those babies don’t survive. Countless others face long hospitalizations and may suffer developmental delays or lifelong disabilities, such as blindness, cerebral palsy, and respiratory disease. In the U.S. alone, prematurity results in $26.2 billion in healthcare and related costs – to say nothing of the emotional toll on families. A recent cost analysis demonstrated that $19.5 million or more could be saved for every 100,000 women evaluated for short cervix and treated with vaginal progesterone as appropriate.

# # #

About Cervilenz Inc.
Cervilenz Inc. manufactures and markets the CerviLenz® device– an innovative medical device that measures vaginal cervical length to help identify and manage pregnant women at high risk for premature birth. Dedicated to making a difference in the world of prematurity, Cervilenz Inc. donates a portion of revenue to charitable organizations that advance maternal and fetal health globally. Founded in 2008, the company headquarters is in Chagrin Falls, a suburb of Cleveland, Ohio. The CerviLenz device was designed and is manufactured in Ohio by Interplex Medical, LLC. The device is single-use and made of recyclable plastic. The CerviLenz device is cleared for sale in the U.S. and has its CE Mark and ISO 13485 Certification. For more information, visit www.cervilenz.com or contact Melanie Sweeney, Vice President of Marketing (440.337.4253 or melanie@cervilenz.com).

About Interplex Medical, LLC
Interplex Medical is a division of Interplex Industries, Inc. FDA registered and ISO 1385 certified, Interplex Medical is located in Milford, Ohio. Interplex Industries was founded in 1958 and is headquartered in College Point, NY. Interplex Industries provides services to the communications, electronics, industrial, medical and automotive markets with facilities in the United States, Mexico, China, Singapore, India, Malaysia, Korea, Scotland, France, Germany and Hungary. For more information, visit www.interplexmedical.com or contact Al Hoffmann, Director of Business Development, North America (248.918.8514 or alhoffmann@interplex.com)

CerviLenz
100 N. Main Street, Suite 300
Chagrin Falls, OH 44022
440.337.4250

This release was published on openPR.